Axovant Sciences (AXON) Upgraded by ValuEngine to “Buy”

Axovant Sciences (NASDAQ:AXON) was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Thursday.

Several other equities research analysts have also weighed in on AXON. Oppenheimer reaffirmed a “hold” rating on shares of Axovant Sciences in a research report on Monday, July 9th. BidaskClub raised Axovant Sciences from a “strong sell” rating to a “sell” rating in a research report on Tuesday, October 16th. Zacks Investment Research lowered Axovant Sciences from a “hold” rating to a “sell” rating in a research report on Monday, August 13th. Cowen reaffirmed a “hold” rating on shares of Axovant Sciences in a research report on Thursday, September 20th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Axovant Sciences in a research report on Monday, August 13th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $4.56.

Shares of AXON opened at $2.08 on Thursday. Axovant Sciences has a 12-month low of $1.02 and a 12-month high of $6.59. The company has a current ratio of 2.34, a quick ratio of 2.34 and a debt-to-equity ratio of 1.48.

Axovant Sciences (NASDAQ:AXON) last announced its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.33). On average, sell-side analysts forecast that Axovant Sciences will post -1.67 earnings per share for the current year.

In related news, Director George Bickerstaff bought 25,000 shares of the company’s stock in a transaction on Thursday, August 9th. The shares were purchased at an average cost of $2.07 per share, with a total value of $51,750.00. Following the completion of the transaction, the director now directly owns 50,000 shares of the company’s stock, valued at $103,500. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.00% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of AXON. Tower Research Capital LLC TRC increased its holdings in shares of Axovant Sciences by 1,627.0% during the second quarter. Tower Research Capital LLC TRC now owns 62,139 shares of the biotechnology company’s stock valued at $141,000 after purchasing an additional 58,541 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Axovant Sciences by 2,519.0% during the first quarter. JPMorgan Chase & Co. now owns 183,223 shares of the biotechnology company’s stock valued at $244,000 after purchasing an additional 176,227 shares during the period. GSA Capital Partners LLP acquired a new position in shares of Axovant Sciences during the second quarter valued at $338,000. Paloma Partners Management Co acquired a new position in shares of Axovant Sciences during the second quarter valued at $356,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Axovant Sciences by 183.1% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 495,450 shares of the biotechnology company’s stock valued at $1,120,000 after purchasing an additional 320,450 shares during the period. 9.32% of the stock is currently owned by institutional investors.

Axovant Sciences Company Profile

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.

Featured Article: How are institutional investors different from individual investors?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply